Results for tag: "Creon"

The Creon market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat exocrine pancreatic insufficiency (EPI), a condition in which the pancreas does not produce enough digestive enzymes. These drugs are used to replace the enzymes that are not being produced, allowing the body to digest food properly. The Creon market is composed of both prescription and over-the-counter drugs, and is expected to grow in the coming years due to an increasing prevalence of EPI. Some of the companies in the Creon market include AbbVie, Allergan, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more